Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr joins Natalie Stoberman from the Proactive newsroom to break down the significance of the preliminary phase 2 data of its ONA-XR treatment for metastatic breast cancer.
ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor that is orally administered. Lehr says preliminary phase 2 findings have highlighted a four month progression free survival rate of 44%, along with favourable safety and tolerability.